Daniel Keravich

Principal and Owner, Chesapeake OTC Regulatory Strategies LLC

Daniel P Keravich is the Principal and Owner of Chesapeake OTC Regulatory Strategies LLC, a consumer health care consulting firm that specializes in providing regulatory strategies, solutions, and support to the OTC healthcare industry. His company specializes in helping sponsors with OTC Switch, providing regulatory affairs strategy and policy advise and currently helps OTC companies with OTC monograph reform. He currently serves as a senior advisor role to CHPA on OTC Monograph reform for OMUFA II. Mr. Keravich has over 35 years of pharmaceutical research and regulatory affairs experience including leadership roles at FDA within the OTC Division, NIH, and GSK Consumer Healthcare, now known as Haleon.

Mr. Keravich’s educational background includes: A Master of Business Administration (MBA), from Loyola College, Sellinger School of Business and Management in Baltimore, MD. A Master of Science from Massachusetts College of Pharmacy and Allied Health Professions in Boston, Massachusetts. A Bachelor of Science (BS), Pharmacy | Northeastern University College of Pharmacy and Allied Health Profession, Boston, Massachusetts and he has also completed his Regulatory Affairs Certification (RAC) in May of 2011.